IGF1 and breast carcinoma: Initial findings from larger clinical trials using anti-IGF neutralizing antibodies were discouraging, as a Phase Ib/II study of xentuzumab, exemestane, and everolimus (mTOR inhibitor) combination therapy for advanced HR+ breast cancer (NCT02123823) was discontinued early due to no change in PFS in the overall participant population [169].